Robert Hofmeister - 09 Dec 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role
Chief Scientific Officer
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Dec 2021
Net transactions value
$0
Form type
4
Filing time
10 Dec 2021, 15:30:23 UTC
Next filing
19 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TCRR Common Stock 45,850 09 Dec 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 09 Dec 2021 Common Stock 100,000 $5.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.